Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 5/20 | 0.35 |
| ▸ | CTSL | P07711 | 2/20 | 0.35 |
| ▸ | CTSB | P07858 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CTSH | P09668 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | KLK7 | P49862 | 1/20 | 0.32 |
| ▸ | PTGES | O14684 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | METAP2 | P50579 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17471357 | 0.81 | SMN1; SMN2 (0.38) | SMN1; SMN2CTSKCTSLCTSBCTSH | |
| SCHEMBL14776505 | 0.81 | TSHR (0.33) | TSHREPHX1 | |
| SCHEMBL14776927 | 0.79 | TSHR (0.34) | TSHR | |
| SCHEMBL631150 | 0.79 | SMN1; SMN2 (0.35) | SMN1; SMN2CTSKCTSLCTSBTSHR | |
| SCHEMBL3902375 | 0.79 | TSHR (0.47) | SMN1; SMN2TSHR | |
| SCHEMBL14413242 | 0.77 | TSHR (0.37) | CTSKCTSLCTSBTSHRCTSH | |
| SCHEMBL16591159 | 0.77 | SMN1; SMN2 (0.38) | SMN1; SMN2CTSKCTSLCTSBCTSH | |
| SCHEMBL2316985 | 0.76 | TSHR (0.48) | SMN1; SMN2TSHREPHX1 | |
| SCHEMBL26935991 | 0.76 | TSHR (0.48) | SMN1; SMN2TSHREPHX1 | |
| SCHEMBL17213620 | 0.76 | TSHR (0.47) | SMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3253735-B1 | LATENT ACIDS AND THEIR USE | BASF SE (DE) | 2021-03-31 | — | — | EP | disclosed |
| US-9994538-B2 | Latent acids and their use | BASF SE (DE) | 2018-06-12 | — | — | US | disclosed |
| US-20180009775-A1 | LATENT ACIDS AND THEIR USE | BASF SE (DE) | 2018-01-11 | — | — | US | disclosed |
| EP-2420890-B1 | Positive photosensitive resin composition, method for forming cured film and liquid crystal display device | FUJIFILM CORP (JP) | 2017-03-01 | — | — | EP | disclosed |
| EP-2613198-B1 | PHOTOSENSITIVE RESIN COMPOSITION, OXIME SULFONATE COMPOUND, METHOD FOR FORMING CURED FILM, CURED FILM, ORGANIC EL DISPLAY DEVICE, AND LIQUID CRYSTAL DISPLAY DEVICE | FUJIFILM CORP (JP) | 2016-12-28 | — | — | EP | disclosed |
| WO-2016124493-A1 | LATENT ACIDS AND THEIR USE | BASF SE (DE) | 2016-08-11 | — | — | WO | disclosed |
| US-8728708-B2 | Photosensitive resin composition, oxime sulfonate compound, method for forming cured film, cured film, organic EL display device, and liquid crystal display device | FUJIFILM CORPORATION (JP) | 2014-05-20 | — | — | US | disclosed |
| US-8628907-B2 | Positive photosensitive resin composition, method for forming cured film, cured film, organic el display device and liquid crystal display device | FUJIFILM CORPORATION (JP) | 2014-01-14 | — | — | US | disclosed |
| US-20140005409-A1 | POSITIVE PHOTOSENSITIVE RESIN COMPOSITION, METHOD FOR FORMING CURED FILM, CURED FILM, ORGANIC EL DISPLAY DEVICE AND LIQUID CRYSTAL DISPLAY DEVICE | FUJIFILM CORPORATION (JP) | 2014-01-02 | — | — | US | disclosed |
| EP-2613198-A1 | PHOTOSENSITIVE RESIN COMPOSITION, OXIME SULFONATE COMPOUND, METHOD FOR FORMING CURED FILM, CURED FILM, ORGANIC EL DISPLAY DEVICE, AND LIQUID CRYSTAL DISPLAY DEVICE | FUJIFILM Corporation (JP) | 2013-07-10 | — | — | EP | disclosed |
| US-20130171415-A1 | PHOTOSENSITIVE RESIN COMPOSITION, OXIME SULFONATE COMPOUND, METHOD FOR FORMING CURED FILM, CURED FILM, ORGANIC EL DISPLAY DEVICE, AND LIQUID CRYSTAL DISPLAY DEVICE | FUJIFILM CORPORATION (JP) | 2013-07-04 | — | — | US | disclosed |
| US-20120045616-A1 | POSITIVE PHOTOSENSITIVE RESIN COMPOSITION, METHOD FOR FORMING CURED FILM, CURED FILM, ORGANIC EL DISPLAY DEVICE AND LIQUID CRYSTAL DISPLAY DEVICE | FUJIFILM CORPORATION (JP) | 2012-02-23 | — | — | US | disclosed |
| EP-2420890-A1 | Positive photosensitive resin composition, method for forming cured film, cured film, organic el display device and liquid crystal display device | Fujifilm Corporation (JP) | 2012-02-22 | — | — | EP | disclosed |
| US-20110281040-A1 | LIQUID CRYSTAL DISPLAY ELEMENT, POSITIVE TYPE RADIATION SENSITIVE COMPOSITION, INTERLAYER INSULATING FILM FOR LIQUID CRYSTAL DISPLAY ELEMENT, AND FORMATION METHOD THEREOF | JSR CORPORATION (JP) | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180009775-A1 | LATENT ACIDS AND THEIR USE | LTA, C1S, C9 | SMN1; SMN2 4885/4885CTSK 805/4885CTSL 500/4885 |
| US-20120045616-A1 | POSITIVE PHOTOSENSITIVE RESIN COMPOSITION, METHOD FOR FORMING CURED FILM, CURED FILM, ORGANIC EL DISPLAY DEVICE AND LIQUID CRYSTAL DISPLAY DEVICE | PELP1, EED, ARCN1 | SMN1; SMN2 4316/4885CTSK 2527/4885CTSL 917/4885 |
| US-20140005409-A1 | POSITIVE PHOTOSENSITIVE RESIN COMPOSITION, METHOD FOR FORMING CURED FILM, CURED FILM, ORGANIC EL DISPLAY DEVICE AND LIQUID CRYSTAL DISPLAY DEVICE | STRA6, NR2E3, CRKL | SMN1; SMN2 3658/4885CTSK 2845/4885CTSL 2051/4885 |
| US-20130171415-A1 | PHOTOSENSITIVE RESIN COMPOSITION, OXIME SULFONATE COMPOUND, METHOD FOR FORMING CURED FILM, CURED FILM, ORGANIC EL DISPLAY DEVICE, AND LIQUID CRYSTAL DISPLAY DEVICE | OXER1, OXSR1, RAD51 | SMN1; SMN2 2126/4885CTSK 3593/4885CTSL 3205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.